分红方面，泰格医药A股上市后累计派现24.58亿元。近三年，累计派现11.54亿元。 机构持仓方面，截止2025年9月30日，泰格医药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4836.25万股，相比上期增加2509.69万股。中欧医疗健康混合A（003095）位居第四大流 通股东，持股2885.17万股，相比上期增加121.78万股。华宝中证医疗ETF（512170）位居第五大流通股 东，持股1456.80万股，相比上期减少266.25万股。易方达创业板ETF（159915）位居第八大流通股东， 持股1125.86万股，相比上期减少188.83万股。华泰柏瑞沪深300ETF（510300）位居第十大流通股东， 持股877.79万股，为新进股东。兴全商业模式混合(LOF)A（163415）退出十大流通股东之列。 融资方面，泰格医药当日融资买入5628.18万元。当前融资余额7.24亿元，占流通市值的1.62%，融资余 额低于近一年30%分位水平，处于低位。 融券方面，泰格医药1月8日融券偿还2.41万股，融券卖出300.00股，按当日收盘价计算，卖出金额1.82 万元；融券余量4.58万股 ...

泰格医药今年以来股价跌5.51%，近5个交易日涨2.09%，近20日涨3.51%，近60日跌13.66%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 12月19日，泰格医药盘中上涨2.03%，截至10:17，报51.33元/股，成交1.95亿元，换手率0.68%，总市值 441.96亿元。 资金流向方面，主力资金净流入594.29万元，特大单买入1725.09万元，占比8.83%，卖出2167.20万元， 占比11.10%；大单买入4843.08万元，占比24.80%，卖出3806.68万元，占比19.50%。 截至9月30日，泰格医 ...

Core Viewpoint - Tiger Med's stock price has shown a decline of 4.42% year-to-date, with significant drops over various trading periods, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - Cumulative cash dividends since the A-share listing amount to 2.458 billion yuan, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400, with an average of 0 shares per shareholder [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3]. Market Activity - On November 26, Tiger Med's stock rose by 2.08% to 51.92 yuan per share, with a trading volume of 154 million yuan and a turnover rate of 0.53% [1]. - The stock has experienced a net inflow of 8.478 million yuan from major funds, with significant buying and selling activity noted [1]. Business Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV of clinical trials [1]. - The company's revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [1]. Industry Classification - Tiger Med is classified under the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [2]. - The company is associated with various concept sectors, including mid-cap, margin financing, social security heavy positions, medical devices, and internet healthcare [2].

资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 泰格医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：互联医疗、中盘、 融资融券、社保重仓、医疗器械等。 11月24日，泰格医药盘中上涨2.02%，截至10:24，报50.59元/股，成交1.69亿元，换手率0.59%，总市值 435.59亿元。 截至9月30日，泰格医药股东户数4.84万，较上期减少6.01%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，泰格医药实现营业收入50.26亿元，同比减少0.82%；归母净利润10.20亿元，同比增长 25.4 ...

11月20日，泰格医药盘中下跌2.00%，截至10:53，报51.32元/股，成交2.64亿元，换手率0.90%，总市值 441.88亿元。 资金流向方面，主力资金净流出2263.55万元，特大单买入253.23万元，占比0.96%，卖出287.90万元， 占比1.09%；大单买入4660.36万元，占比17.64%，卖出6889.23万元，占比26.08%。 泰格医药今年以来股价跌5.53%，近5个交易日跌13.21%，近20日跌2.49%，近60日跌22.59%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 泰格医药所属申万行业为： ...

Core Viewpoint - Tiger Med's stock price has experienced a decline of 3.17% year-to-date, with a significant drop of 21.49% over the past 60 days, indicating potential challenges in the market [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2] - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and China Europe Medical Health Mixed A, which increased its holdings by 1.218 million shares [3]

Core Viewpoint - The stock of Tigermed Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 50.94 billion yuan, reflecting mixed investor sentiment and market performance [1]. Company Overview - Tigermed Pharmaceutical, established on December 15, 2004, and listed on August 17, 2012, is based in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1]. - The main business segments include clinical trial services (52.60% of revenue), clinical trial technical services (45.21%), and other services (2.19%) [1]. Financial Performance - For the period from January to September 2025, Tigermed reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400. The average circulating shares per person remained unchanged at 0 [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.10 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3].

Core Viewpoint - Tiger Med's stock has experienced a decline in recent trading sessions, reflecting challenges in revenue and profit margins, alongside notable changes in shareholder composition and market activity [1][2][3] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is based in Hangzhou, Zhejiang Province, and specializes in providing professional clinical research services for pharmaceutical and health-related products [1] - The company's main business segments include clinical trial services, data management, regulatory submissions, and medical testing services, with clinical trial-related services accounting for 52.60% of revenue [1] Financial Performance - For the first half of 2025, Tiger Med reported revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company's stock price has declined by 4.00% year-to-date, with a 4.29% drop over the last five trading days and a 13.40% decrease over the past 20 days [1] Shareholder Composition - As of June 30, 2025, the number of shareholders decreased by 4.14% to 51,500, with an average of 0 shares per shareholder [2] - The top shareholders include China Europe Medical Health Mixed Fund, which reduced its holdings by 3.32 million shares, and Hong Kong Central Clearing Limited, which increased its holdings by 439,610 shares [3] Market Activity - On October 23, Tiger Med's stock fell by 2.01%, trading at 52.15 yuan per share with a total market capitalization of 44.903 billion yuan [1] - The net outflow of main funds was 3.8256 million yuan, with significant selling pressure observed in large orders [1]

Core Viewpoint - On October 22, Tiger Med experienced a decline of 0.89% with a trading volume of 327 million yuan, indicating a negative net financing position for the day [1] Financing Summary - On October 22, Tiger Med had a financing buy-in amount of 30.85 million yuan and a financing repayment of 39.86 million yuan, resulting in a net financing outflow of 9.01 million yuan [1] - As of October 22, the total financing and securities lending balance for Tiger Med was 783 million yuan, with the financing balance accounting for 1.99% of the circulating market value, which is above the 60th percentile level over the past year [1] Securities Lending Summary - On October 22, Tiger Med repaid 12,500 shares in securities lending and sold 8,100 shares, amounting to 431,100 yuan based on the closing price [1] - The securities lending balance stood at 323,640 yuan with a remaining quantity of 60,800 shares, exceeding the 70th percentile level over the past year [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province, and specializes in providing professional clinical research services for pharmaceutical and health-related products [2] - The company's main business revenue composition includes 52.60% from clinical trial-related services and laboratory services, and 45.21% from clinical trial technical services [2] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] Dividend Information - Since its A-share listing, Tiger Med has distributed a total of 2.458 billion yuan in dividends, with 1.154 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top circulating shareholders include China Europe Medical Health Mixed Fund, Hong Kong Central Clearing Limited, and Huabao CSI Medical ETF, with varying changes in their holdings [3]

Core Insights - On October 15, Tiger Med saw a 2.51% increase in stock price with a trading volume of 466 million yuan, while the net financing buy was negative at 336.68 million yuan [1] - The company reported a revenue of 3.25 billion yuan for the first half of 2025, a year-on-year decrease of 3.21%, and a net profit of 383 million yuan, down 22.22% year-on-year [2] Financing and Margin Trading - On October 15, Tiger Med had a financing buy of 36.32 million yuan and a financing repayment of 39.69 million yuan, resulting in a total financing balance of 7.54 billion yuan [1] - The current financing balance of 7.51 billion yuan accounts for 1.85% of the market capitalization, which is below the 50th percentile level over the past year, indicating a low position [1] Short Selling - On October 15, Tiger Med repaid 4,900 shares in short selling and sold 2,300 shares, with a selling amount of 126,700 yuan based on the closing price [1] - The short selling balance stands at 375.09 million yuan, which is above the 80th percentile level over the past year, indicating a high position [1] Shareholder Information - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top ten circulating shareholders include notable funds, with changes in their holdings indicating varying levels of investment interest [3]